Sans consultant since November, NPPA faces multiple legal hurdles

According to the information gathered by The Indian Express, at least 26 cases have been filed post November 30, 2017, and high courts have given relief to the firms in most of the cases by granting stay orders against any “coercive action” by NPPA.

Read More

Prices of Patented Medicines in India : To Regulate or Not to Regulate?

Medicines with valid patents generally enjoy exemption from price regulation in most countries. In India, the Drugs (Prices Control) Order lays down the rules for regulation of prices of medicines through a National List of Essential Medicines, inserted as Schedule-I of theDPCO.

Read More

Drug price control: Niti Aayog for exemption if below-10 per cent fall in rate

If a drug molecule has seen a price reduction of less than 10 per cent under the current price “control methodology”, the Central government should exempt it from price control, according to a Niti Aayog proposal, which is currently under discussion.

Read More

Exclusive: India rejects U.S. request on price caps on medical…

India has told the United States it won’t abstain from capping prices for more medical devices, regardless of pressure to rethink its stance after price controls on heart stents and knee implants spoilt the market for some U.S. firms, sources familiar with the matter said.

Read More

Following NPPA order to provide price-regulated stents, say hospitals

Hospitals across the Capital maintained that they have revised and are offering the new, low-priced stents rates as per direction of the National Pharmaceutical Pricing Authority (NPPA) which came in earlier this month. Cardiologists have welcomed the lowered-price list stating that the benefit will be seen immediately.

Read More

Price control not the best way to achieve affordability: NPPA Chairman Bhupendra Singh

While the National Pharmaceutical Pricing Authority (NPPA) revised the ceiling price on coronary stents on Monday, its Chairman Bhupendra Singh stated on Friday that that the price control is not the best option to achieve affordability. “If you ask me, I don’t consider that price control is the best option to achieve affordability.

Read More

After cardiac stents, price cap on hip implants awaited

After price caps on cardiac stents and knee implants, a cap is now eagerly awaited on hip implants, which too are highly priced due to excessive profiteering by manufacturers, distributors as well as healthcare providers. “The price control on all implants has been widely discussed.

Read More